Where does Rapport Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$107.28M+3.8%	-$111.48M-14.1%	-$97.7M-10.6%	-$88.31M-10.8%	-$79.7M-1.8%
Depreciation and amortization	$1M-1.7%	$1.02M+0.5%	$1.01M+3.8%	$975K+4.7%	$931K+11.0%
Stock-based compensation	$21.78M+15.5%	$18.86M+15.2%	$16.37M+10.5%	$14.82M+15.9%	$12.78M+24.9%
Change in accounts receivable	——	——	——	——	——
Change in accounts payable	$4.51M+88.6%	$2.39M—	——	——	——
Change in accrued liabilities	$2.34M-62.0%	$6.17M+85.3%	$3.33M+70.7%	$1.95M+274%	$521K+40.4%
Change in other assets	——	——	——	$5.83M—	——
Non-cash operating lease expense	$2.2M+8.4%	$2.03M+25.0%	$1.63M+33.2%	$1.22M+36.1%	$897K+39.7%
Net cash from operating activities	-$80.3M+8.2%	-$87.47M-13.3%	-$77.22M-1.4%	-$76.17M-12.9%	-$67.45M-4.0%
Capital expenditures	$411K-33.3%	$616K-8.5%	$673K-0.9%	$679K-58.2%	$1.62M-32.5%
Purchases of investments	$341.92M-3.6%	$354.78M+46.4%	$242.27M-3.2%	$250.39M-33.4%	$375.97M-0.4%
Proceeds from maturities/sales of investments	$161.69M-3.7%	$167.93M-35.8%	$261.73M-4.3%	$273.59M+1.2%	$270.41M+28.9%
Net cash from investing activities	-$170.56M+9.0%	-$187.47M—	——	——	——
Proceeds from issuance of common stock	$2.15M+59.6%	$1.35M+109%	$643.75K+6,676%	$9.5K-15.6%	$11.25K+60.7%
Payment of debt issuance costs	——	——	——	——	——
Net cash from financing activities	$271.31M+0.2%	$270.79M+0.1%	$270.48M+530,457%	-$51K-100%	$159.37M-28.5%
Net increase (decrease) in cash	$20.45M+592%	-$4.16M—	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	——	——	——	——	——
Accrued expenses and other liabilities	$2.34M-62.0%	$6.17M+85.3%	$3.33M+70.7%	$1.95M+274%	$521K+40.4%
Increase Decrease In Operating Lease Liabilities	$1.11M+122%	$500K+74.8%	$286K-37.1%	$455K-21.8%	$582K-13.1%
Increase (Decrease) in Other Operating Assets	——	——	$878K+70.2%	$516K+10,420%	-$5K+94.0%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	$5.83M—	——
Operating lease right-of-use asset amortization	$2.2M+8.4%	$2.03M+25.0%	$1.63M+33.2%	$1.22M+36.1%	$897K+39.7%
Proceeds from disposition of marketable securities and other investments	$161.69M-3.7%	$167.93M-35.8%	$261.73M-4.3%	$273.59M+1.2%	$270.41M+28.9%
Proceeds From Sale Of Short Term Investments	——	——	——	——	——
Payments For Repurchase Of Unvested Restricted Common Stock	——	——	——	——	——
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1	——	——	——	——	——
Offering Costs	——	——	——	——	——
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	——
Free cash flow	-$80.71M+8.4%	-$88.09M-13.1%	-$77.89M-1.4%	-$76.85M-11.3%	-$69.07M-2.7%
Free cash flow	-$80.71M+8.4%	-$88.09M-13.1%	-$77.89M-1.4%	-$76.85M-11.3%	-$69.07M-2.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Rapport Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.